Immunovant Stock Story


USD 4.76  0.38  8.68%   

Immunovant Net Cash Flow from Financing is comparatively stable at the moment as compared to the past year. Immunovant reported Net Cash Flow from Financing of 440.58 Million in 2021. Share Based Compensation is likely to gain to about 23.4 M in 2022, whereas Free Cash Flow is likely to drop (81.1 M) in 2022. This post will review Immunovant. We will check if it is still possible for Immunovant to minimize net losses this year. Here I will also review some basic indicators that Immunovant investors should consider in July.
Published over a month ago
View all stories for Immunovant | View All Stories

Immunovant Sentiment by News Outlets

Macroaxis News:
prnewswire News
zacks News
benzinga news

Immunovant Historical Investor Sentiment

Investor biases related to Immunovant's public news can be used to forecast risks associated with investment in Immunovant. The trend in average sentiment can be used to explain how an investor holding Immunovant can time the market purely based on public headlines and social activities around Immunovant. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Immunovant's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Immunovant's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Immunovant's news discussions. The higher the estimate score, the more favorable is the investor's outlook on Immunovant.

Immunovant Twitter Pulse

Investors have realized that leveraging social media to get the fastest information affecting stock prices isn't a theory anymore, it is a reality, and Twitter offers a platform that can outpace even the most trustworthy news aggregators. The influence of social media outlets on stock markets and stock prices of entities such as Immunovant has been proven in recent years. We extract public sentiment from Twitter posts that could be utilized to determine whether Immunovant's prices will increase or decrease.
Twitter's metrics such as likes, followers, and engagement can be good indicators of the reliance and probability of reaction to a specific tweet regarding Immunovant. Our Twitter sentiment analysis of Immunovant Stock helps investors make informed decisions by leveraging the power of the community. It is a perfect supplementary tool for any beginner or an experienced trader.

Is Immunovant about to turn this around?

This firm is undervalued at 6.35 per share with modest projections ahead.
The company retains a Market Volatility (i.e., Beta) of 1.6488, which attests to a somewhat significant risk relative to the market. Let's try to break down what Immunovant's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Immunovant will likely underperform. Even though it is essential to pay attention to Immunovant current price history, it is always good to be careful when utilizing equity current price movements. Our philosophy towards determining any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Immunovant exposes twenty-eight different technical indicators, which can help you to evaluate its performance. Immunovant has an expected return of -0.29%. Please be advised to check out Immunovant maximum drawdown, as well as the relationship between the skewness and day typical price to decide if Immunovant performance from the past will be repeated at some point in the near future.

How important is Immunovant's Liquidity

Immunovant financial leverage refers to using borrowed capital as a funding source to finance Immunovant ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Immunovant financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Immunovant's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for Immunovant, but it might be worth checking our own buy vs. sell analysis

Another angle On Immunovant

Immunovant has a total of one hundred fifteen million outstanding shares. Immunovant retains majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company outstanding shares. 64.67 (percent) of Immunovant outstanding shares that are owned by insiders attests that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Also note that almost one million one hundred fifty thousand invesors are currently shorting Immunovant expressing very little confidence in its future performance.

Ownership Breakdown

Retail Investors-0.92

Our take on today Immunovant gain

The potential upside is down to 7.73 as of today. Immunovant exhibits very low volatility with skewness of 0.22 and kurtosis of 0.74. However, we advise investors to further study Immunovant technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Immunovant's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Immunovant's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Immunovant Implied Volatility

Immunovant's implied volatility exposes the market's sentiment of Immunovant stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Immunovant's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Immunovant stock will not fluctuate a lot when Immunovant's options are near their expiration.

Whereas some firms in the biotechnology industry are either recovering or due for a correction, Immunovant may not be performing as strong as the other in terms of long-term growth potentials. Taking everything into account, as of the 8th of June 2022, we see that Immunovant slowly supersedes the market. The firm is undervalued with above average probability of bankruptcy within the next 24 months. Our overall 90 days 'Buy-Sell' recommendation on the firm is Cautious Hold.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Immunovant. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to